{"nctId":"NCT01263925","briefTitle":"Prostaglandin E1 in Outpatients With Intermittent Claudication","startDateStruct":{"date":"2001-04"},"conditions":["Stage II Peripheral Arterial Occlusive Disease","Intermittent Claudication Fontaine Stage II PAOD"],"count":561,"armGroups":[{"label":"Alprostadil","type":"EXPERIMENTAL","interventionNames":["Drug: Alprostadil (Prostaglandin E1)","Drug: Placebo to Pentoxifylline oral"]},{"label":"Pentoxifylline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pentoxifylline","Drug: Placebo to Alprostadil (Prostaglandin E1) intravenous"]}],"interventions":[{"name":"Alprostadil (Prostaglandin E1)","otherNames":["Prostavasin"]},{"name":"Pentoxifylline","otherNames":["Trental®"]},{"name":"Placebo to Pentoxifylline oral","otherNames":[]},{"name":"Placebo to Alprostadil (Prostaglandin E1) intravenous","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with Peripheral Arterial Occlusive Disease (PAOD) of the lower extremity in Fontaine stage II\n* Maximum walking distance on the treadmill (12 %, 3 km/h) between 30 and 150 m\n* Stable Intermittent Claudication of at least 6 months standing with no acute shortening of walking distance over the past 3 months\n* Stenoses or occlusions below the Femoral Bifurcation (above-knee or below-knee type) confirmed by duplex US or angiography\n* Ankle/brachial index ≤ 0.90 with a decrease in systolic ankle pressure of ≥ 10 % after maximum loading (maximum walking distance on the treadmill at 3 km/h, 12 %)\n* The patient is physically and mentally capable of participating in the trial\n* Patient age \\> 40 years, male and female\n* Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent\n* Patient is willing and able to comply with all trial requirements\n\nExclusion Criteria:\n\n* Surgical or other interventional measures performed on the affected extremity and Prostaglandin treatment within the 6 months immediately prior to the trial\n* Rest pain and Necroses\n* Systolic ankle pressure less than 50 mmHg\n* Change in maximum walking distance during the one-week Run-in Phase of more than ± 25 % of Baseline\n* Successful physical walking training within the 6 months immediately prior to the trial\n* Inflammatory vascular diseases\n* Polyneuropathy in Diabetes Mellitus\n* Diseases limiting walking distance (Arthrosis, inflammatory diseases of the joints, neurological disease, diseases of the Vertebral Column, cardiopulmonary diseases)\n* History of Pulmonary Oedema\n* Myocardial infarction within the past 6 months\n* Pregnancy or nursing\n* Known hypersensitivity to any components of the trial medication or comparative drug\n* Renal insufficiency, compensated retention (creatinine \\> 2.0 mg/dL)\n* Severe retinal Haemorrhage\n* Massive Haemorrhage\n* Known existing malignant diseases\n* Vasoactive concomitant medication (e.g. Naftidrofuryl, Pentoxifylline, Buflomedil, Cilostazol), or other Prostaglandins\n* Untreated or uncontrolled Hypertension (systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 mmHg)\n* Previous participation of the patient in the present trial\n* Participation of the patient in a trial with the same objectives within the past 6 months, or is currently participating in another trial\n* Illness of the patient due to alcohol or drug-abuse within the past 6 months\n* Serious illness of the patient that the investigator considers to compromise his/her participation in the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline","description":"The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 2 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"12.22"},{"groupId":"OG001","value":"1.98","spread":"3.61"}]}]}]},{"type":"PRIMARY","title":"Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline","description":"The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"3.00"},{"groupId":"OG001","value":"2.36","spread":"2.69"}]}]}]},{"type":"PRIMARY","title":"Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline","description":"The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 1 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":"1.92"},{"groupId":"OG001","value":"1.58","spread":"2.59"}]}]}]},{"type":"SECONDARY","title":"Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1","description":"The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 2 divided by the pain-free walking distance after Period 1 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.64"},{"groupId":"OG001","value":"1.24","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1","description":"The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance after Period 1 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"1.53"},{"groupId":"OG001","value":"1.57","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2","description":"The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance after Period 2 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.85"},{"groupId":"OG001","value":"1.28","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline","description":"The ratio of maximum walking distance was calculated by the maximum walking distance after Period 1 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.53"},{"groupId":"OG001","value":"1.43","spread":"1.34"}]}]}]},{"type":"SECONDARY","title":"Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline","description":"The ratio of maximum walking distance was calculated by the maximum walking distance after Period 2 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"0.86"},{"groupId":"OG001","value":"1.76","spread":"1.78"}]}]}]},{"type":"SECONDARY","title":"Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1","description":"The ratio of maximum walking distance was calculated by the maximum walking distance after Period 2 divided by the maximum walking distance after Period 1 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"0.50"},{"groupId":"OG001","value":"1.21","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline","description":"The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"1.40"},{"groupId":"OG001","value":"1.99","spread":"1.61"}]}]}]},{"type":"SECONDARY","title":"Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 1","description":"The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance after Period 1 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.87"},{"groupId":"OG001","value":"1.42","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 2","description":"The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance after Period 2 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"0.58"},{"groupId":"OG001","value":"1.17","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 1","description":"Scores for subscales were calculated by summing non-missing item scores ranging from 1 (not at all; best possible outcome) to 4 (extremely; worst possible outcome) divided by the number of non-missing items. Hence each subscale score ranges from 1 (best possible outcome) to 4 (worst possible outcome). For subscales 'Mood' and 'Treatment expectation' five items each had to be reversed in order. Additionally, subjects were asked to assess their general health and quality of life on an ordinal scale between 0 (very good) and 10 (very poor).\n\nNegative changes show a decrease from Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.44"},{"groupId":"OG001","value":"-0.27","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.40"},{"groupId":"OG001","value":"-0.18","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.51"},{"groupId":"OG001","value":"-0.18","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.34"},{"groupId":"OG001","value":"-0.08","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.34"},{"groupId":"OG001","value":"-0.02","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.42"},{"groupId":"OG001","value":"0.01","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"1.48"},{"groupId":"OG001","value":"-0.36","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"1.58"},{"groupId":"OG001","value":"-0.38","spread":"1.78"}]}]}]},{"type":"SECONDARY","title":"Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 3","description":"Scores for subscales were calculated by summing non-missing item scores ranging from 1 (not at all; best possible outcome) to 4 (extremely; worst possible outcome) divided by the number of non-missing items. Hence each subscale score ranges from 1 (best possible outcome) to 4 (worst possible outcome). For subscales 'Mood' and 'Treatment expectation' five items each had to be reversed in order. Additionally, subjects were asked to assess their general health and quality of life on an ordinal scale between 0 (very good) and 10 (very poor).\n\nNegative changes show a decrease from Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.57"},{"groupId":"OG001","value":"-0.41","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.58"},{"groupId":"OG001","value":"-0.35","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.64"},{"groupId":"OG001","value":"-0.22","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.48"},{"groupId":"OG001","value":"-0.12","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.43"},{"groupId":"OG001","value":"-0.04","spread":"0.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.51"},{"groupId":"OG001","value":"0.11","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"1.83"},{"groupId":"OG001","value":"-0.48","spread":"1.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"2.09"},{"groupId":"OG001","value":"-0.39","spread":"2.20"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":276},"commonTop":["Nausea","Abdominal Pain Upper","Influenza Like Illness","Hypertension","Vertigo"]}}}